25.23
-0.28 (-1.10%)
| Previous Close | 25.51 |
| Open | 25.41 |
| Volume | 71,909 |
| Avg. Volume (3M) | 369,758 |
| Market Cap | 1,214,775,168 |
| Price / Earnings (Forward) | 285.71 |
| Price / Sales | 12.05 |
| Price / Book | 3.47 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -11.86% |
| Operating Margin (TTM) | -5.09% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | 29.90% |
| Total Debt/Equity (MRQ) | 7.64% |
| Current Ratio (MRQ) | 4.73 |
| Operating Cash Flow (TTM) | 14.63 M |
| Levered Free Cash Flow (TTM) | 39.10 M |
| Return on Assets (TTM) | -0.79% |
| Return on Equity (TTM) | -2.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bullish | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | BioLife Solutions, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.50 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 2.84% |
| % Held by Institutions | 100.53% |
| 52 Weeks Range | ||
| Median | 32.00 (26.83%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 32.00 (26.83%) | Buy | 26.35 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AEBERSOLD SARAH | - | 26.99 | -217 | -5,857 |
| BERARD TODD | - | 26.99 | -351 | -9,473 |
| DUROSS AMY | - | 26.84 | -4,000 | -107,340 |
| FOSTER KAREN A. | - | 26.99 | -415 | -11,201 |
| MATHEW ABY J. | - | 26.99 | -526 | -14,197 |
| WERNER SEAN | - | 26.99 | -110 | -2,969 |
| WICHTERMAN TROY | - | 26.99 | -584 | -15,762 |
| Aggregate Net Quantity | -6,203 | |||
| Aggregate Net Value ($) | -166,799 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.95 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DUROSS AMY | Director | 26 Nov 2025 | Sell (-) | 2,000 | 26.68 | 53,360 |
| WERNER SEAN | Officer | 25 Nov 2025 | Automatic sell (-) | 110 | 26.99 | 2,969 |
| MATHEW ABY J. | Officer | 25 Nov 2025 | Automatic sell (-) | 526 | 26.99 | 14,197 |
| FOSTER KAREN A. | Officer | 25 Nov 2025 | Automatic sell (-) | 415 | 26.99 | 11,201 |
| AEBERSOLD SARAH | Officer | 25 Nov 2025 | Automatic sell (-) | 217 | 26.99 | 5,857 |
| WICHTERMAN TROY | Officer | 25 Nov 2025 | Automatic sell (-) | 584 | 26.99 | 15,762 |
| BERARD TODD | Officer | 25 Nov 2025 | Automatic sell (-) | 351 | 26.99 | 9,473 |
| DUROSS AMY | Director | 25 Nov 2025 | Sell (-) | 2,000 | 26.99 | 53,980 |
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence |
| 17 Nov 2025 | Announcement | BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025 |
| 06 Nov 2025 | Announcement | BioLife Solutions Reports Third Quarter 2025 Financial Results |
| 23 Oct 2025 | Announcement | BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025 |
| 07 Oct 2025 | Announcement | BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |